Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 41 for:    MINOXIDIL (FOR MEN) OR LONOLOX OR WOMEN'S ROGAINE OR ROGAINE (FOR MEN) OR LONITEN OR THEROXIDIL OR ROGAINE EXTRA STRENGTH (FOR MEN) OR U-10,858 OR MEN'S ROGAINE OR REGAINE FOR MEN OR MINOXIDIL OR MINOXIDIL EXTRA STRENGTH (FOR MEN) OR REGAINE FOR WOMEN OR MINODYL

Topical Minoxidil Versus Topical Glyceryl Trinitrate in Treatment of Chronic Anal Fissure

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03528772
Recruitment Status : Recruiting
First Posted : May 18, 2018
Last Update Posted : May 21, 2018
Sponsor:
Information provided by (Responsible Party):
Sameh Emile, Mansoura University

Brief Summary:
This randomized trial aims to compare two topical treatments in the treatment of chronic anal fissure: minoxidil gel and glycreyl trintrate cream. The endpoint of the study is the duration of healing of anal fissure whereas secondary endpoints include adverse effects of each treatment and recurrence of anal fissure

Condition or disease Intervention/treatment Phase
Anal Fissure Drug: Minoxidil Drug: Glyceryl trinitrate Not Applicable

Detailed Description:

All participants who fulfill the inclusion criteria and give consent for participation in the trial and will be included and randomly assigned to either group I (5% Minoxidil gel) or group II (0.2% GTN cream) with a 1:1 allocation. Randomization will be carried out using online software (Research Randomizer Version 4.0 at https://www.randomizer.org).

Patients will receive the topical agent in unlabeled red or blue containers. The code of each color will be known to a pharmacist who will not take any part in patients' care, follow-up, data collection/analysis or accessing outcomes of the study. The investigators will be blinded to the nature of content of each container and the outcome assessor will not be aware of the study nature.

Interventions Eligible patients will be randomized into two equal groups: groups I will receive topical 5% Minoxidil gel (Minoxidil Forte 5% topical gel 60 gm; Pharmacare Egypt Co., Cairo, Egypt) and group II will receive topical 0.2% GTN cream (Nitoglycerine-Glycerile Tinitrade 0.2%, 30 gm; E.S.A.G Pharma Co., Cairo, Egypt). Both agents used in the study will be relabeled by a pharmacist who will not take any part in the study in terms of patients' care, follow-up, data collection/analysis or accessing outcomes. Both topical agents will be placed in identical containers of 60 gm and labeled with blue or red colors. The color code will remain undefined till the end of trial, data analysis, and interpretation of results except for the same pharmacist. The containers will be distributed to the patients by the outpatient's department nurse in the hospital.

Patients will be advised to apply approximately 2 cm of the gel/cream (equal to 3 gm) on the perianal area three times per day for 4 weeks. The first dose of drugs will be given at home on the same day of the first visit. During the first visit, patients will be taught to self-administer the topical gel/cream. The patients will be instructed to take laxatives to avoid constipation and to avoid using other topical preparations during the study period.

Follow-up Patients will be followed in the general and colorectal surgery outpatient clinics for a period of three months. Patients will be advised to visit the outpatient clinic every week for one month, then biweekly in the 2nd and 3rd months after starting treatment. In case of intolerable adverse events patients will be advised to visit the outpatient clinic at any other time point during the trial. At each visit the anal fissure will be inspected and the extent of healing will be assessed by a surgical resident who is unaware of the nature of the study. Patients will be asked about the improvement in their symptoms, particularly anal pain and bleeding. Pain will be measured at each visit by the Visual Analog Scale (VAS) ranging from no pain "0" to worst possible pain "10". Blood pressures will be measured and any decrease of > 15 mmHg from the basal pressure measured at the first visit will be considered significant. Adverse effects induced by the topical agents as itching, headache, palpitation, dizziness, excess perianal hair growth, and hypersensitivity reaction will be recorded. Itching will be assessed by 5-D pruritus scale. The continence state will be assessed using Wexner continence score.


Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 70 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Topical 5% Minoxidil Versus 0.2%Topical Glyceryl Trinitrate in Treatment of Chronic Anal Fissure: a Randomized Controlled Trial
Estimated Study Start Date : May 10, 2018
Estimated Primary Completion Date : July 30, 2019
Estimated Study Completion Date : August 30, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Minoxidil
Patients in this arm will receive topical treatment with Minoxidil forte 5% gel three times per days for 4 weeks
Drug: Minoxidil
application of minoxidil forte 5% gel three time per day on the anus for four weeks
Other Name: Topical Minoxidil treatment

Active Comparator: Glyceryl trinitrate
Patients in this arm will receive topical treatment with glyceryl trinitrate 0.2% cream three times per days for 4 weeks
Drug: Glyceryl trinitrate
application of glyceryl trinitrate 0.2% cream three time per day on the anus for four weeks
Other Name: Topical GTN treatment




Primary Outcome Measures :
  1. Healing duration [ Time Frame: three months ]
    the duration of time needed for complete healing defined as reepithelialization of the anoderm at the site of anal fissure


Secondary Outcome Measures :
  1. Anal pain [ Time Frame: three months ]
    degree of relief of anal pain as measured by visual analogue scale (VAS) from 0 to 10 where 0 indicates no pain and 10 indicates the worst severe pain.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients of both genders presenting with chronic anal fissure of more than 6 weeks in duration
  • Ageing between 18 and 65 years old.

Exclusion Criteria:

  • Pregnant patients.
  • Patients with cardiovascular disease or heart failure.
  • Patients on antihypertensive medications.
  • Patients with recurrent anal fissure after previous sphincterotomy.
  • Patients with prior history of anal surgery.
  • Patients with coexisting anorectal diseases or inflammatory bowel diseases.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03528772


Contacts
Layout table for location contacts
Contact: Sameh Emile, M.D. 01006267150 sameh200@hotmail.com
Contact: Mostafa Shalaby, M.D. 01001645917 mostafashalaby@mans.edu.eg

Locations
Layout table for location information
Egypt
Mansoura university hospital Recruiting
Mansourah, Dakahlia, Egypt, 35516
Contact: Sameh Emile, M.D    01006267150    sameh200@hotmail.com   
Contact: Sameh H Emile, M.D.         
Sponsors and Collaborators
Mansoura University
Investigators
Layout table for investigator information
Principal Investigator: Sameh Emile, M.D. Mansoura University

Layout table for additonal information
Responsible Party: Sameh Emile, Lecturer of general surgery, Mansoura University
ClinicalTrials.gov Identifier: NCT03528772     History of Changes
Other Study ID Numbers: mansoura50
First Posted: May 18, 2018    Key Record Dates
Last Update Posted: May 21, 2018
Last Verified: May 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Sameh Emile, Mansoura University:
anal fissure, minoxidil, glycreyl trinitrate

Additional relevant MeSH terms:
Layout table for MeSH terms
Fissure in Ano
Anus Diseases
Rectal Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Minoxidil
Nitroglycerin
Antihypertensive Agents
Vasodilator Agents